Clinical Trials
30 trialsReiki-Brachy
University of Utah
DOVE
Yonsei University
iCaRe2
University of Nebraska
DP-04
AstraZeneca
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Ohio State University Comprehensive Cancer Center
ANTARES
Instituto do Cancer do Estado de São Paulo
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
M.D. Anderson Cancer Center
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Rutgers, The State University of New Jersey
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Rutgers, The State University of New Jersey
3D Printed Custom Applicators for HDR BT (DISCO)
Royal North Shore Hospital
Image-Guided Gynecologic Brachytherapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Dana-Farber Cancer Institute
EMBRAVE
Erasmus Medical Center
TRIDENT
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
MIPEX
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
ASQ-GYO
Barbara Ann Karmanos Cancer Institute
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
Northwestern University
NYSCF Scientific Discovery Biobank
New York Stem Cell Foundation Research Institute
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Northwestern University
A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer
Zhejiang Cancer Hospital
HPV-VIM
Baylor College of Medicine
GynCAT
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
The Affiliated Hospital of Qingdao University
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
Shanghai Bovax Biotechnology Co., Ltd.
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
HRYZ Biotech Co.
RetroBT
Zhejiang Cancer Hospital